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Objectives: The primary objectives of the study are:
1. To assess the effect of hydroxychloroquine (HCQ) in reducing SARS-CoV-2 viral shedding by PCR in infected
pregnant women with mild symptoms.
2. To assess the efficacy of HCQ to prevent SARS-CoV-2 infection in pregnant women in contact with an infected or
suspected case.
3. To evaluate the effect of HCQ in preventing the development of the COVID-19 disease in asymptomatic
SARS-CoV-2-infected pregnant women.
The secondary objectives are:
1. To determine the effect of HCQ on the clinical course and duration of the COVID-19 disease in SARS-CoV-2-infected
pregnant women.
2. To determine the impact of HCQ on the risk of hospitalization and mortality of SARS-CoV-2-infected pregnant
women.
3. To assess the safety and tolerability of HCQ in pregnant women.
4. To describe the clinical presentation of SARS-CoV-2 infection during pregnancy.
5. To describe the effects of maternal SARS-CoV-2 infection on pregnancy and perinatal outcomes by treatment group.
(Continued on next page)© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: raquel.gonzalez@isglobal.org
†Raquel González and Laura García-Otero contributed equally to this work.
1ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain
2Consorcio de Investigación Biomédica en Red de Epidemiología y Salud
Pública (CIBERESP), Barcelona, Spain
Full list of author information is available at the end of the article
González et al. Trials          (2020) 21:607 Page 2 of 3(Continued from previous page)
6. To determine the risk of vertical transmission (intra-utero and intra-partum) of SARS-CoV-2.
Trial design: Randomized double-blind placebo-controlled two-arm multicentre clinical trial to evaluate the safety and
efficacy of HCQ to prevent and/or minimize SARS-CoV-2 infection during pregnancy. Participants will be randomized to
receive a 14-day oral treatment course of HCQ or placebo, ratio 1:1.
Participants: Study population: pregnant women undergoing routine prenatal follow up or attending emergency
units at the participating hospitals who report either symptoms/signs suggestive of COVID-19 disease or close contact
with a suspected or confirmed COVID-19 case.
Inclusion criteria
Women will be invited to participate in the trial and sign an informed consent if they meet the following inclusion
criteria.
• Presenting with fever (≥37.5°C) and/or one mild symptom suggestive of COVID-19 disease (cough, dyspnoea, chills,
odynophagia, diarrhoea, muscle pain, anosmia, dysgeusia, headache) OR being contact* of a SARS-CoV-2 confirmed or
suspected case in the past 14 days
• More than 12 weeks of gestation (dated by ultrasonography)
• Agreement to deliver in the study hospitals
Exclusion criteria
• Known hypersensitivity to HCQ or other 4-amonoquinoline compounds
• History of retinopathy of any aetiology
• Concomitant use of digoxin, cyclosporine, cimetidine
• Known liver disease
• Clinical history of cardiac pathology including known long QT syndrome
• Unable to cooperate with the requirements of the study
• Participating in other intervention studies
• Delivery onset (characterized by painful uterine contractions and variable changes of the cervix, including some
degree of effacement and slower progression of dilatation up to 5 cm for first and subsequent labours)
The study participants will be stratified by clinical presentation and SARS-CoV-2 PCR results. Assignment of participants
to study groups will be as follows:
• SARS-CoV-2-PCR confirmed, infected pregnant women:
a. symptomatic (n=100)
b. asymptomatic (n=100)
• SARS-CoV-2 PCR negative pregnant women in contact* with a SARS-CoV-2-infected confirmed or suspected case
(n=514).
*The ECDC definition of close contact will be followed.
The trial will be conducted in five hospitals in Spain: Hospital Clínic of Barcelona, Hospital Sant Joan de Déu and
Hospital de la Santa Creu i Sant Pau, in Barcelona, and HM Puerta del Sur and Hospital Universitario de Torrejón, in
Madrid.
Intervention and comparator: Participants will be randomized to HCQ (400 mg/day for three days, followed by 200
mg/day for 11 days) or placebo (2 tablets for three days, followed by one tablet for 11 days).
Main outcomes: The primary outcome is the number of PCR-confirmed infected pregnant women assessed from
collected nasopharyngeal and oropharyngeal swabs at day 21 after treatment start (one week after treatment is
completed).
Randomisation: Allocation of participants to study arms will be done centrally by the trial’s Sponsor (the Barcelona
Institute for Global Health, ISGlobal) by block randomization. This method will ensure balanced allocation to both arms.
The electronic CRF will automatically assign a study number to each participant, depending on her study group and
recruitment site. Each number will be related to a treatment number, which assigns them to one of the study arms.
Blinding (masking): Participants, caregivers, investigators and those assessing the outcomes will be blinded to group
assignment. Study tablets (HCQ and placebo) will be identically packaged in small opaque bottles.
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Numbers to be randomised (sample size): This study requires 200 SARS-CoV-2 infected and 514 contact pregnant
women, randomised 1:1 with 100 and 227 respectively in each study arm.
Trial Status: Protocol version 1.0, from May 8th, 2020. Recruitment is ongoing (first patient recruited the 19th May 2020
and recruitment end anticipated by December 2020).
Trial registration: EudraCT number: 2020-001587-29, registered 2 April 2020.
Clinicaltrials.gov identifier: NCT04410562, retrospectively registered 1 June 2020.
Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In
the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves
as a summary of the key elements of the full protocol.
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Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-04557-y.
Additional file 1. Full Study Protocol.
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